A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma

This study is testing three treatment options — LBL-024 alone, LBL-024 combined with LBL-007, or LBL-024 combined with toripalimab (an immune checkpoint drug) — for people with advanced melanoma (a serious form of skin cancer). Researchers want to see which approach is safest and most effective. **You may be eligible if...** - You are 18 or older - You have advanced melanoma with measurable tumor(s) - Your daily functioning is good (ECOG 0–1) - You are expected to survive at least 12 weeks - You are willing to use effective contraception during treatment and for 6 months after **You may NOT be eligible if...** - You have received a live vaccine within 4 weeks of starting the study - You have had major surgery or another major procedure recently - You have active or recurring autoimmune disease - You have serious heart or brain vascular disease - You have an active infection - You are pregnant or breastfeeding - You have a history of mental illness, alcohol abuse, or drug addiction affecting judgment Talk to your doctor to see if this trial is right for you.